Trial Profile
Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Mivavotinib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 24 Jul 2020 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 24 Jun 2020 Results presented at the 111th Annual Meeting of the American Association for Cancer Research - II
- 09 Jan 2020 Status changed from active, no longer recruiting to discontinued.